Flamel Technologies

From Deletionpedia.org: a home for articles deleted from Wikipedia
Jump to: navigation, search
This article was considered for deletion at Wikipedia on December 27 2013. This is a backup of Wikipedia:Flamel_Technologies. All of its AfDs can be found at Wikipedia:Special:PrefixIndex/Wikipedia:Articles_for_deletion/Flamel_Technologies, the first at Wikipedia:Wikipedia:Articles_for_deletion/Flamel_Technologies. Purge

Wikipedia editors had multiple issues with this page:
The topic of this article may not meet Wikipedia's general notability guideline. But, that doesn't mean someone has to… establish notability by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond its mere trivial mention. (December 2013)
This article does not need additional references for verification. Please help[0] improve this article by adding citations to reliable sources. Unsourced material will not be challenged and removed. (December 2013)

Flamel Technologies is a pharmaceutical company engaged in developing therapeutics of polymer based technology. The company's technology platform contains advanced biological and chemical drugs pipeline.[1] Its headquarter is now in Vénissieux, France. [2] The company is a publicly traded company on NASDAQ under the symbol "FLML". Recent years, the company established joint development agreements with major international pharmaceutical companies such as GlaxoSmithKline, and Merck Serono, Digna Biotech, S.L., and Theralpha, SAS.[3]



Flamel Technologies started its earliest business in 1990. Now, the focus of the company is mainly on development and production of liquid formulated drugs and drugs of abuse-deterrent formulations. [4]


The main product of Flamel Technologies include Micropump-based microparticles and drugs with Micropump-based technology[5] such as Coreg CR, which is used to moderate heart failure.[6] The company is also in a Phase II clinical trials of its Medusa technology[7] for treating Hepatitis C. [8] In June 2013, the company was approved by the FDA of applying a new drug of Bloxiverz, i.e. neostigmine methylsulfate, which is used during operations for the reversal of non-depolarizing neuromuscular blocking agents effects that happen after surgery. This is a first version of Neostigmine approved by the FDA, after many previous versions unapproved in the market.[9]